Article
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.
Cancer discovery - 1 May 2017
Shih Alan H, Meydan Cem, Shank Kaitlyn, Garrett-Bakelman Francine E, Ward Patrick S, Intlekofer Andrew M, Nazir Abbas, Stein Eytan M, Knapp Kristina, Glass Jacob, Travins Jeremy, Straley Kim, Gliser Camelia, Mason Christopher E, Yen Katharine, Thompson Craig B, Melnick Ari, Levine Ross L
Abstract excerpt
Genomic studies in acute myeloid leukemias (AML) have identified mutations that drive altered DNA methylation, including TET2 and IDH2 Here, we show that models of AML resulting from TET2 or IDH2 mutations combined with FLT3ITD mutations are sensitive to 5-azacytidine or to the IDH2 inhibitor AG-221, respectively. 5-azacytidine and AG-221 treatment induced an attenuation of aberrant DNA methylation and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.